Please assess the completion status of the following clinical trial:

Trial Title: An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed culture and/or GeneXpert positive pulmonary TB.~* Rifampicin resistance detected using at least two susceptibility testing assays (GeneXpert, HainMTBDRplus or phenotypic) using a sputum sample during screening.~* Provide written informed consent prior to all trial-related procedures including HIV testing.~* Male or female aged 18 years and older.~* Body weight between 40 and 90 kg, inclusive.~* Women of non-childbearing potential or participants of either sex who are using or willing to use effective methods of birth control~Exclusion Criteria:~* A participant who in the opinion of the investigator is unlikely to cope with regular visits to the trial site either because of travel constraints, or because of drug or alcohol abuse, or other reason.~* Known at screening to have XDR-TB or pre-XDR-TB (i.e. fluoroquinolone or second-line injectable drug (SLID) resistance i.e. to capreomycin, amikacin and kanamycin).~* Previous history of treatment for MDR-TB or XDR-TB or previous treatment with bedaquiline.~* Currently on MDR-TB treatment for more than 2 weeks.~* Any participant with a Karnofsky score \< 50.~* Known allergy to any of the trial drugs or related substances.~* Having participated in other clinical studies within 8 weeks prior to trial start where investigational agents were used that may potentially impact current trial outcome.~* Presence (or evidence) of symptomatic neuropathy grade 3 or higher.~* Epilepsy where drugs prolonging QT interval are used.~* Participant who is pregnant, breast-feeding (and not willing to stop), or planning to conceive a child within 6 months of cessation of treatment.~* Incompatibility between microbiological and clinical/ radiological findings (i.e. where the clinical and/or radiological findings are discordant with microbiological testing suggesting laboratory contamination).~* Participants with ECG abnormalities, in particular QT prolongation.~* Any pre-existing laboratory abnormality which in the opinion of the investigator will place the participant at risk. Patients with any of the following baseline laboratory abnormalities will be excluded from the study:~  * Creatinine grade 2 or worse (\>1.4 times ULN)~ * Hemoglobin level grade 4 (HB \<6.5g/dL)~ * Platelets grade 3 or worse (\<49999 x 109/L)~ * ALT grade 3 or worse (\>5 times ULN)~ * Total bilirubin grade 3 or worse (\>2.5 times ULN)~* Specific prior or concurrent medication/treatments (see Restrictions section below, Table 3).~* Rifampicin monoresistant TB.~* Fluoroquinolone and/or SLID resistance. Although in South Africa, the standard of care does not single out MDR-TB with fluoroquinolone or aminoglycoside resistance at initiation of MDR-TB treatment, in this study the Hain MTBDRsl LPA will be used on the sputum sample to exclude any pre-XDR and XDR cases from participation in the study (results from the LPA and phenotypic DST testing on the isolate will be available 3-6 weeks later).~All inclusion and no exclusion criteria must be met prior to enrolment and randomisation. Whenever the investigator has reason to suspect that there might be a health problem (other than TB) participation should only be considered after discussing the case with the medical monitor. Note: Participants who are currently on, or have previously been on drug-sensitive TB treatment are not excluded from participation.~Post-randomisation exclusion criteria:~• Fluoroquinolone and/or SLID resistance detected on DST using the isolate. Note: A woman who falls pregnant during the treatment phase of the trial will not be excluded but will be counselled regarding potential termination of pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional treatment 21-24 months (Type: ACTIVE_COMPARATOR): Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol.
- Interventional treatment 6-9 months (Type: EXPERIMENTAL): Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (\<50kg) or 1000mg (\>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures.

Based on this trial design, predict the completion outcome and termination type (if applicable).